ProtAffin AG is a biotechnology company in Austria and UK developing a novel class of next-generation biopharmaceuticals for respiratory disease, inflammation and oncology. The Company’s lead product, PA401, is a decoy IL-8 protein in preclinical development for lung diseases where neutrophils cause chronic lung damage, including COPD. PA401 has demonstrated differentiated pharmacology compared to competitors in preclinical models of COPD and will enter Phase 1 studies in mid 2012. The Company has generated a broad product pipeline using its proprietary CellJammer® discovery technology, an efficient engine for the discovery of novel biologics applicable to over 500 glycan-binding proteins identified by the Company. ProtAffin has raised €18 million in venture funding from an international consortium of leading European and North American investors.
For more information on ProtAffin, please visit www.protaffin.com.